AnGes Obtains Conditional Approval in Japan for HGF Gene Therapy to Treat Critical Limb Ischemia
April 04, 2019 22:00 ET
|
AnGes MG, Inc.
TOKYO, April 05, 2019 (GLOBE NEWSWIRE) -- AnGes, Inc., a biopharmaceutical company focused on developing innovative gene-based medicines for treating serious diseases, announced today that they have...
Vasomune Therapeutics and AnGes, Inc. enter into a Multi-Million Dollar Global Co-Development Agreement to Advance an Innovative Platform Targeting Vascular Leakage
July 31, 2018 07:00 ET
|
AnGes MG, Inc.
TOKYO and TORONTO, July 31, 2018 (GLOBE NEWSWIRE) -- Vasomune Therapeutics (“Vasomune”), a Toronto-based spin-out from Sunnybrook Research Institute and MaRS Innovation, and AnGes, Inc. (Tokyo,...
AnGes Announces First Patient Treated with NF-kappa B Decoy in Phase Ib Study to Treat Discogenic Low Back Pain
February 27, 2018 19:31 ET
|
AnGes MG, Inc.
TOKYO, Feb. 28, 2018 (GLOBE NEWSWIRE) -- AnGes, Inc., a biopharmaceutical company focused on developing innovative gene-based medicines for serious diseases, announced today the treatment of the...
AnGes Submits Application for Marketing Approval to PMDA for HGF gene therapy for Critical Limb Ischemia
January 22, 2018 22:11 ET
|
AnGes MG, Inc.
TOKYO, Jan. 23, 2018 (GLOBE NEWSWIRE) -- AnGes, Inc., a biopharmaceutical company focused on developing innovative gene-based medicines for serious diseases, announced today the submission of an...
AnGes Starts Global Phase III Clinical Trials of Collategene(R) for Critical Limb Ischemia
October 05, 2014 20:20 ET
|
AnGes MG, Inc.
TOKYO, Oct. 6, 2014 (GLOBE NEWSWIRE) -- AnGes MG, Inc. ("AnGes") announces that it has commenced the global phase III clinical trials of Collategene® with the enrollment of patients in the...
AnGes Enters Into the Definitive Agreement With Mitsubishi Tanabe Pharma for Exclusive Marketing Rights of Collategene(R) in the United States
October 23, 2012 23:00 ET
|
AnGes MG, Inc.
TOKYO, Oct. 24, 2012 (GLOBE NEWSWIRE) -- AnGes MG Inc. ("AnGes") announced today that the company has entered into a definitive agreement with Mitsubishi Tanabe Pharma Corporation (Head Office:...